SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment adds public-company financial and capital markets experience as the company accelerates its global expansion and advances regulatory initiatives.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. She joins SS Innovations after serving as CFO at Vicarious Surgical, another robotic surgical technology developer, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the balance sheet.
The appointment comes at a critical time for SS Innovations, which is pursuing broader commercialization of its SSi Mantra robotic surgical platform and preparing for U.S. Food and Drug Administration review. The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program, which welcomed 33 healthcare professionals from seven countries. This underscores the company's emphasis on surgeon education alongside technology deployment.
“Sarah’s deep expertise in medtech finance and capital markets will be invaluable as we scale our operations and pursue FDA clearance,” said Dr. Sudhir Srivastava, chairman and CEO of SS Innovations, in a statement. “Her track record of raising capital and managing financial operations at public companies aligns perfectly with our strategic goals.”
The SSi Mantra system is already in use internationally, and the company is expanding its footprint in markets outside the United States. The addition of Romano signals a focus on financial discipline and strategic capital management as the company navigates the regulatory pathway in the U.S. and continues to grow its international presence.
For more information about SS Innovations and its technologies, visit the company’s newsroom at https://ibn.fm/SSII. Details on the FDA review process for the SSi Mantra system can be found at https://nnw.fm/yY4UM.
